Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/s0959-8049(02)00479-3.
C J A Punt, S Aamdal, B Escudier, W H J Kruit, U Keilholz, L Håkansson, N van Baren, Y Humblet, P Mulders, M-F Avril, A M M Eggermont, C Scheibenbogen, J Uiters, J Wanders, M Delire, T Boon, G Stoter
Affiliations
- PMID: 12504661
- DOI: 10.1016/s0959-8049(02)00479-3
Clinical Trial
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
M Marchand et al. Eur J Cancer. 2003 Jan.
Abstract
Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.
Similar articles
- Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Clinical Trial. - Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D. Derré L, et al. Clin Cancer Res. 2017 Feb 1;23(3):717-725. doi: 10.1158/1078-0432.CCR-16-1189. Epub 2016 Aug 12. Clin Cancer Res. 2017. PMID: 27521445 Clinical Trial. - Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S. Atanackovic D, et al. J Immunol. 2004 Mar 1;172(5):3289-96. doi: 10.4049/jimmunol.172.5.3289. J Immunol. 2004. PMID: 14978137 - Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
Adam V, Wauters I, Vansteenkiste J. Adam V, et al. Expert Opin Biol Ther. 2014 Mar;14(3):365-76. doi: 10.1517/14712598.2014.880421. Epub 2014 Jan 24. Expert Opin Biol Ther. 2014. PMID: 24456101 Review.
Cited by
- MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy.
Lisica Šikić N, Petrić Miše B, Tomić S, Spagnol G, Matak L, Juretić A, Spagnoli G. Lisica Šikić N, et al. Cancers (Basel). 2023 Sep 23;15(19):4697. doi: 10.3390/cancers15194697. Cancers (Basel). 2023. PMID: 37835391 Free PMC article. - Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer.
Saillard M, Cenerenti M, Romero P, Jandus C. Saillard M, et al. Vaccines (Basel). 2021 May 4;9(5):454. doi: 10.3390/vaccines9050454. Vaccines (Basel). 2021. PMID: 34064410 Free PMC article. Review. - A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
McQuade JL, Homsi J, Torres-Cabala CA, Bassett R, Popuri RM, James ML, Vence LM, Hwu WJ. McQuade JL, et al. BMC Cancer. 2018 Dec 19;18(1):1274. doi: 10.1186/s12885-018-5193-9. BMC Cancer. 2018. PMID: 30567529 Free PMC article. Clinical Trial. - Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.
Baurain JF, Robert C, Mortier L, Neyns B, Grange F, Lebbe C, Ulloa-Montoya F, De Sousa Alves PM, Gillet M, Louahed J, Jarnjak S, Lehmann FF. Baurain JF, et al. ESMO Open. 2018 Jul 25;3(5):e000384. doi: 10.1136/esmoopen-2018-000384. eCollection 2018. ESMO Open. 2018. PMID: 30094070 Free PMC article. - Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
Grob JJ, Mortier L, D'Hondt L, Grange F, Baurain JF, Dréno B, Lebbe C, Robert C, Dompmartin A, Neyns B, Gillet M, Louahed J, Jarnjak S, Lehmann FF. Grob JJ, et al. ESMO Open. 2017 Nov 14;2(5):e000203. doi: 10.1136/esmoopen-2017-000203. eCollection 2017. ESMO Open. 2017. PMID: 29177094 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources